VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain of his affiliates, terminated pursuant to its terms when the Icahn group’s net long position in the common shares of Bausch + Lomb’s parent company, B
Related Questions
How will the termination of Carl Icahn's director appointment agreement affect Bausch + Lomb's governance and future strategic direction?
What is the expected short‑term impact of this board change on BLCO's share price and trading volume?
Could the removal of Icahn’s influence signal a shift in the company's stance toward activist investors and affect long‑term shareholder value?